36 Krypton learned that “ Shenghe Wanwu ” recently announced the completion of the Pre-A round of financing of tens of millions of yuan, led by Yida Capital, followed by Zhongke Angel and Simple Capital. It is reported that this round of financing transaction was completed in early October this year, and the funds raised will be used for the construction of a GMP-compliant natural product biomanufacturing demonstration line and product application research and development. Explore Capital is the exclusive financial advisor for this round.
Shenghewanwu was established in November 2021. The core team is from the Chinese Academy of Sciences. It is co-founded by academician Zhao Guoping, a molecular microbiologist, and academician Yue Jianmin, an organic chemist. They have rich experience in the research of synthetic biology of natural compounds.
“As a biotechnology company that uses synthetic biology technology to produce natural compounds, Shenghewanwu is doing two types of transformation: one is to provide high-quality, reasonably priced natural compound monomers to the market; on the other hand, hope and medicine, health care Together with scientists or enterprises from product and cosmetic R&D institutions, we will deeply study the functional mechanism and druggability of ginsenoside monomers and other natural compounds, and develop different types of new and high-efficiency products according to the needs of different levels of human health.” Chairman of Shenghewanwu Academician Zhao Guoping said.
At present, Shenghewanwu has obtained 13 groups of 33 patents related to saponin synthesis from the Center for Excellence in Molecular Plant Science, Chinese Academy of Sciences, including the transfer of 15 compounds’ fermentation The yield has reached the level of industrialization. Shenghewanwu’s existing product pipeline mainly covers a variety of natural compounds such as ginsenoside monomers, including rare ingredients such as ginsenoside CK, Rg3, Rh1, Rh2, F1, Rg2 and notoginsenoside R1, R2.
It is understood that the above-mentioned synthesis technology was completed by Zhou Zhihua’s research group at the Center for Excellence in Molecular Plant Science, Chinese Academy of Sciences; for natural compounds such as rare ginsenosides, the team already has a relatively complete research and development chain: from biosynthetic route exploration, synthetic component mining and characterization, cell One-Pot synthesis in the factory, optimization of the path to components, and improvement of product yield.
Ginsenosides, as a representative product of all things in life, have great potential in the markets of pharmaceuticals, health products, functional foods and cosmetics. Prepared by de novo biosynthetic technology, Shenghewanwu can realize the production of various monomer components of ginsenosides with high yield, high purity and low cost. At present, the yield of ginsenosides of the company has increased thousands of times, and the purity exceeds 99.5%.
In terms of platform capabilities, Shengyuewuwu has formed a complete biotechnology platform for pathway analysis, design, reconstruction and directional heterologous synthesis of natural compounds. Based on this platform, the team analyzed the synthetic pathways of more than 20 triterpene saponins including rare ginsenosides, notoginseng saponins (R1, R2 and U) and gypenosides (XIII, XVII and LXXV). In the future, big data will be combined with the biological components and database built by the team in the early stage, and AI technology will be introduced to create rational design of biological components and automatic casting technology of cell factories.
In terms of specific product layout, Shenghewanwu has carried out short-term, medium-term and long-term deployment in combination with the development characteristics of cosmetics, health products and medicines. Specifically: in the short term, focus on the production and sales of cosmetic raw materials; in the medium term, develop health food with verifiable efficacy for the “preventive treatment of diseases” advocated by traditional Chinese medicine or “sub-health” referred to by modern medicine; in the long term (within ten years) , to develop innovative drugs of natural compounds for Alzheimer’s disease, tumors, cardiovascular and cerebrovascular indications and other fields.
Using synthetic biology technology to design and construct artificial cell factories to ferment natural compounds, this new development method has attracted the attention of the academic and industry circles. The new synthesis mode of terpenoid artemisinin is a successful example. In terms of the development of natural compounds, the Chinese scientific community has accumulated a lot of academic progress at the laboratory level, and is gradually moving towards industrialized development and application. Related companies are worthy of follow-up attention.
Investor’s point of view
Wang Yu, investor of Yida Capital: Natural compounds have superior biological activity and are widely used, but traditional biological extraction and chemical synthesis methods have shortcomings such as complex procedures, high costs, and low efficiency, which make further research and development of traditional Chinese medicine Difficulty. Shenghewanwu has opened up multiple biosynthetic pathways of ginsenosides, and can produce natural compounds with high efficiency and low cost, which is of great significance to the development of the modernization of traditional Chinese medicine. Yida Capital is willing to accompany the growth of all things in depth and promote the development of synthetic biology together.
Luo Kun, project leader of the China Science Angel Fund: Synthetic biology is known as one of the key technologies that will change the future of mankind, and it is a very dynamic sunrise industry. Shenghewanwu originated from one of the first batch of “973” synthetic biology projects in the country. Starting from the heterologous synthesis of rare ginsenosides, the company has created a synthetic biology platform integrating upstream and downstream, and more than ten products have reached industrialization standards. . The founding team has more than ten years of accumulation in the biosynthesis of natural compounds and the field of fungal microorganisms, and has mastered the world’s leading synthetic biology technology. Zhongke Angel is optimistic about the solid technical foundation and industrial layout of Shenghewanwu in the field of synthetic biology, and expects to grow together with Shenghewanwu to realize “biological synthesis of everything”.
Reference article:
media reports
36Kr Entrepreneurship in the Investment World
related events
- “Shenghe Wanwu” completed the PreA round of financing of tens of millions of yuan, and Yida Capital led the investment2022-12-05
- Hechen Biotech completed tens of millions of yuan in angel round financing2022-10-10
- Huili Biotech completed nearly 300 million yuan in round A financing2022-07-04
- Weiyuan Synthetic Biotech completed an angel round financing of nearly 100 million yuan2022-05-30
- Xinbeilai Biotech completed the pre-A round of financing of 10 million yuan, and Kaitai Capital led the investment2021-09-30
This article is transferred from: https://readhub.cn/topic/8luvQgqSRP0
This site is only for collection, and the copyright belongs to the original author.